Veloxity Labs, a bioanalytical contract research organization (CRO) specializing in accelerating therapeutic development, is proud to announce a partnership with Aplos Analytics. This collaboration ...

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, ...

Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water submersionNew findings demonstrate dosing of ...

Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this ...

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the ...

The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.

The Board of Directors of Aqilion AB (publ) ("Aqilion" or the "Company") has on 11 February 2025, based on the authorization granted by the Annual General Meeting on 10 June 2024, resolved to carry ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Lipella's LP-310 Phase 2a trial showed strong efficacy and safety for oral lichen planus. The company plans a Phase 2b trial ...

Professor Saoirse O’Sullivan, Vice President Translational Science at Artelo Biosciences, is scheduled to deliver a presentation entitled, “A Cannabidiol Cocrystal (ART12.11) Tablet Has Comparable ...

头孢曲松、头孢他啶均属于临床常用的第三代头孢菌素类抗菌药物，具有广谱抗菌活性和相对较低的肾毒性，临床应用广泛。尽管这两种药物在作用机制、抗菌谱和适应症方面有许多相似之处，但它们之间也存在一些明显的差异。那么具体两者有何区别？临床上该如何选择？本文一起 ...

Rallybio (RLYB) announced that the first participant has been dosed in the Phase 2 trial investigating RLYB212 in pregnant women at higher risk ...